• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Immunocore Holdings plc

    9/10/25 4:35:00 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMCR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001955244
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Immunocore Holdings plc
    SEC File Number
    001-39992
    Address of Issuer
    92 Park Drive Milton Park
    Abingdon, Oxfordshire
    UNITED KINGDOM
    OX14 4RY
    Phone
    44-1235-438600
    Name of Person for Whose Account the Securities are To Be Sold
    David M. Berman
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    American Depositary Shares
    J.P. Morgan Securities LLC
    390 Madison Avenue - 6th Floor
    New York � NY � 10017
    13500049396505038706809/10/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    American Depositary Shares09/10/2025Stock Option ExerciseIssuerCheckbox not checked13500009/10/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    The shares covered by this filing are stock options that will be exercised today or within three months from the date of this filing.
    Date of Notice
    09/10/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/09/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for David M. Berman

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $IMCR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMCR

    DatePrice TargetRatingAnalyst
    8/25/2025$48.00Buy
    Jefferies
    5/27/2025$65.00Buy
    Deutsche Bank
    12/13/2024$74.00 → $35.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2024$72.00 → $38.00Outperform → Neutral
    Mizuho
    10/24/2024$24.00Sell
    UBS
    10/7/2024Buy → Neutral
    Guggenheim
    4/29/2024$74.00Outperform
    Leerink Partners
    11/20/2023$60.00Overweight
    JP Morgan
    More analyst ratings

    $IMCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Immunocore with a new price target

    Jefferies resumed coverage of Immunocore with a rating of Buy and set a new price target of $48.00

    8/25/25 8:53:43 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Deutsche Bank initiated coverage on Immunocore with a new price target

    Deutsche Bank initiated coverage of Immunocore with a rating of Buy and set a new price target of $65.00

    5/27/25 9:10:28 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Immunocore from Overweight to Equal-Weight and set a new price target of $35.00 from $74.00 previously

    12/13/24 8:04:38 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

    Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.EDINBURGH, Scotland and LONDON, Sept. 10, 2025 /PRNewswire/ -- Resolution Therapeutics ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces the appointment of Lucy Singah as Chief Financial Officer (CFO) and Daniel Kennedy as Chief Business Officer (CB

    9/10/25 3:30:00 AM ET
    $IMCR
    $ALXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Pharmaceuticals

    Immunocore to present at upcoming investor conferences

    Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, September 3, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.         Cantor Global Healthcare Conference         Fireside Chat: Friday, September 5, 2025, at 8:35 a.m. EDT         H.C. Wainwright 27th Annual Global Investment Conference         1x

    9/4/25 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore reports second quarter financial results and provides a business update

    KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Phase 1 single ascending dose HBV data for IMC-I109V will be presented at the 2025 AASLD Liver Meeting Cash, cash equivalents and marketable securities of $883 million as of June 30, 2025 Conference call today, August 7 at 8:00 AM ET, 1:00 PM BST (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, August 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and de

    8/7/25 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

    4 - Immunocore Holdings plc (0001671927) (Issuer)

    3/19/25 6:40:21 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pao William

    4 - Immunocore Holdings plc (0001671927) (Issuer)

    5/19/25 4:15:17 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Ratcliffe Peter John

    4 - Immunocore Holdings plc (0001671927) (Issuer)

    5/19/25 4:15:21 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Bell John Irving

    4 - Immunocore Holdings plc (0001671927) (Issuer)

    5/19/25 4:15:09 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    SEC Filings

    View All

    SEC Form 144 filed by Immunocore Holdings plc

    144 - Immunocore Holdings plc (0001671927) (Subject)

    9/10/25 4:35:00 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plc

    SCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)

    8/14/25 1:27:09 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Immunocore Holdings plc (0001671927) (Filer)

    8/7/25 7:40:52 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Leadership Updates

    Live Leadership Updates

    View All

    Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

    Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe

    1/2/25 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Levicept Appoints Eliot Forster as CEO

    Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

    11/30/23 4:00:00 AM ET
    $IMCR
    $IMTX
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immunocore Appoints Siddharth Kaul to its Board of Directors

    Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s

    6/9/22 7:45:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Financials

    Live finance-specific insights

    View All

    Immunocore reports second quarter financial results and provides a business update

    KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Phase 1 single ascending dose HBV data for IMC-I109V will be presented at the 2025 AASLD Liver Meeting Cash, cash equivalents and marketable securities of $883 million as of June 30, 2025 Conference call today, August 7 at 8:00 AM ET, 1:00 PM BST (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, August 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and de

    8/7/25 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

    (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss their financial results and provide a business and portfolio update. Audio

    7/31/25 2:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore reports first quarter financial results and provides a business update

    Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

    5/7/25 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

    SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

    11/14/24 1:28:34 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

    SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

    11/14/24 1:22:39 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

    SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

    11/14/24 6:40:08 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care